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Darunee Buddhari1, Mammen P Mammen7 and Robert V Gibbons8
Abstract
Background: The effect of prior dengue virus (DENV) exposure on subsequent heterologous infection can be
beneficial or detrimental depending on many factors including timing of infection. We sought to evaluate this
effect by examining a large database of DENV infections captured by both active and passive surveillance
encompassing a wide clinical spectrum of disease.
Methods: We evaluated datasets from 17 years of hospital-based passive surveillance and nine years of cohort studies,
including clinical and subclinical DENV infections, to assess the outcomes of sequential heterologous infections. Chi
square or Fisher’s exact test was used to compare proportions of infection outcomes such as disease severity; ANOVA
was used for continuous variables. Multivariate logistic regression was used to assess risk factors for infection outcomes.
Results: Of 38,740 DENV infections, two or more infections were detected in 502 individuals; 14 had three infections.
The mean ages at the time of the first and second detected infections were 7.6 ± 3.0 and 11.2 ± 3.0 years. The shortest
time between sequential infections was 66 days. A longer time interval between sequential infections was associated
with dengue hemorrhagic fever (DHF) in the second detected infection (OR 1.3, 95% CI 1.2-1.4). All possible sequential
serotype pairs were observed among 201 subjects with DHF at the second detected infection, except DENV-4 followed
by DENV-3. Among DENV infections detected in cohort subjects by active study surveillance and subsequent non-study
hospital-based passive surveillance, hospitalization at the first detected infection increased the likelihood of
hospitalization at the second detected infection.
Conclusions: Increasing time between sequential DENV infections was associated with greater severity of the second
detected infection, supporting the role of heterotypic immunity in both protection and enhancement. Hospitalization
was positively associated between the first and second detected infections, suggesting a possible predisposition in
some individuals to more severe dengue disease.
Background
Dengue is a globally important, re-emerging infectious
disease caused by one of four dengue virus serotypes
(DENV-1 to DENV4) with a high degree of antigenic
cross-reactivity. It is estimated that 390 million infections
occur annually, with approximately 96 million resulting in
clinically apparent disease [1]. DENV infections can lead
to diverse outcomes, including subclinical infection, clinic-
ally non-specific illness, dengue fever (DF), and dengue
hemorrhagic fever (DHF).
Many studies have shown that the risk of DHF in non-
infant patients is greater when an initial DENV infection
is followed by a second infection with a different sero-
type [2-7]. All possible orders of infecting serotypes have
been documented in patients with DHF except DENV-4
followed by DENV-1 or DENV-3 [8]. In some popula-
tions, reports indicate that DHF occurs more frequently
with DENV-2 or DENV-3 infections in DENV-1 exposed
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individuals [9,10]. One mechanism underlying this
observation has been postulated to be antibody-
dependent enhancement (ADE) during the second
infection mediated by non-protective heterotypic anti-
bodies arising from the first infection. However, the
timing of the second infection seems to be important
since some degree of short-term protection may be
conferred against subsequent heterologous infection
by the preceding infection [11]. In a population model
of children hospitalized with dengue in Bangkok,
Thailand, the length of this short-term heterologous
protection was estimated to be one to three years [12].
Longer intervals between heterologous infections seem
to increase susceptibility to DHF. An evaluation of
dengue cases from outbreaks in Cuba in 1981 and 1997
suggest that a longer period between infections in-
creases the risk of DHF [13]. In an analysis of repeat
DENV infections from a prospective cohort study of
children in Kamphaeng Phet, Thailand, the ratio of
symptomatic to subclinical infections was found to be
higher when the time from first to second infection was
longer [14].
Some studies have suggested that sequential infection
with two different serotypes may induce sufficient cross-
immunity to confer some degree of protection from a
third or fourth serotype. Primate studies have suggested
that multivalent neutralizing antibodies after two DENV
infections reduce the risk of detectable viremia from
subsequent heterologous infection [15-18]. Among thou-
sands of children hospitalized with dengue in Bangkok,
Thailand, the number of known third and fourth infec-
tions was found to be less than the number of known
second infections indicating some level of multivalent
protection after two heterologous infections [8]. Interest-
ingly, in this same population of hospitalized children,
the ratio of DHF to DF with known second infections
was no different than with known third or fourth infec-
tions. In an analysis of a prospective cohort from Iquitos,
Peru, presumed second infections were more likely to be
symptomatic rather than subclinical as compared to third
or fourth infections [19].
Altogether, these observations highlight the intricate
interplay between host immunity and sequential DENV
infections and suggest that the time between consecutive
infections is an important factor in infection outcome.
In Bangkok and Kamphaeng Phet, Thailand, where
dengue is hyperendemic, our group has conducted pro-
spective cohort studies, hospital-based dengue studies and
public health diagnostic testing for several decades. These
have resulted in a large database containing thousands of
DENV infections. Repeat infections in some of these
datasets have been analyzed previously and published
elsewhere [8,14]. Data used in these prior analyses were
partitioned according to data source to avoid study
biases. In contrast, the current study combines all these
different datasets into a larger single dataset from which
previously unidentified repeat infections could be de-
tected, potentially yielding a wider clinical spectrum of
repeat infections and allowing detection of sequential
serotype pairs which would not otherwise have been
detected.
Methods
Ethics statement
The retrieval and analysis of coded pre-existing data in
this study was approved by the Walter Reed Army Insti-
tute of Research (WRAIR) Institutional Review Board
(IRB), Queen Sirikit National Institute of Child Health
(QSNICH) IRB and Kamphaeng Phet Provincial Hospital
(KPPPH). Public health samples from passive surveil-
lance were originally collected at QSNICH and KPPPH,
and data were analyzed anonymously. Research study
samples were originally collected from QSNICH, KPPPH,
and Kamphaeng Phet (KPP) province according to their
respective approved study protocols, and data were
analyzed according to those protocols. The original
study protocols were approved by the IRBs of WRAIR,
University of Massachusetts Medical School, the Thai
Ministry of Public Health (MOPH), and QSNICH as de-
scribed in earlier publications.
Datasets and locations
Datasets from three types of samples were used to iden-
tify repeat infections in the current study: (1) public
health samples from passive surveillance of hospitalized
DENV infections at QSNICH and KPPPH; (2) research
samples from hospital-based dengue studies at QSNICH
and KPPPH, and (3) research samples from prospective
cohort studies in KPP province. For research samples,
written informed consents were obtained from the par-
ent/guardian of study subjects. QSNICH is a 420-bed
tertiary care pediatric hospital located in Bangkok,
Thailand that serves as the MOPH dengue referral cen-
ter for Bangkok. KPPPH is a 334-bed facility that serves
as the MOPH referral hospital for KPP province, a rural
area of over 700,000 people located approximately
350 km north of Bangkok. Procedures used to generate
each dataset have been detailed elsewhere and are briefly
described here.
Public health samples
Acute and convalescent blood samples from passive sur-
veillance of clinically suspected dengue inpatients at
QSNICH and KPPPH were tested (as described in the
“Laboratory Dengue Assays” section) for evidence of
DENV infection at the Armed Forces Research Institute
of Medical Sciences (AFRIMS) for public health pur-
poses [8]. Testing was requested at the discretion of the
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health care provider for clinically suspected cases. No
specific criteria were required either for hospitalization
or for dengue testing; these were based on the clinical
judgment of the health care provider. Patients admitted
to QSNICH were ≤15 years old; patients at KPPPH
could be of any age. Clinical classification was based on
World Health Organization (WHO) guidelines applic-
able at the time of infection. Dengue cases admitted
from 1994 to 2010 were used for the current analysis.
Hospital-based dengue studies
Hospital-based prospective dengue studies were con-
ducted at KPPPH from 1994–97 and at QSNICH from
1994–2002 [20,21]. Children ≤15 years old who pre-
sented to the hospital outpatient department with fever
≤3 days duration without an obvious source of infection
were enrolled and followed prospectively in the hospital.
Acute and convalescent blood samples were tested (as
described in the “Laboratory Dengue Assays” section) for
DENV infection at AFRIMS. Clinical classification was
based on World Health Organization (WHO) criteria
applicable at the time of infection. Data from dengue cases
from 1994 to 2002 were used for the current analysis.
Prospective cohort studies
Two longitudinal prospective cohort studies were con-
ducted in Kamphaeng Phet, Thailand from 1998–2002
(called KPS1) and from 2004–2007 (called KPS2) [20,21].
Approximately 2000 primary school children were
followed for acute febrile episodes during the presumed
peak DENV transmission season (Jun-Nov/Dec) using
active school absence-based surveillance. Acute and
convalescent blood samples from acute febrile episodes
were tested (as described in the “Laboratory Dengue
Assays” section) for DENV infection at AFRIMS. Quar-
terly (for KPS1) or pre- and post-surveillance season
(for KPS2) blood collections were tested for evidence of
seroconversion to DENV. Subclinical infection was
defined as ≥ four-fold rise in dengue hemagglutination in-
hibition (HAI) titer between scheduled blood collections
[22] confirmed by dengue plaque reduction neutralization
test (PRNT) [23], but without an acute symptomatic
DENV infection detected during the intervening period.
Symptomatic infection was defined as an acute febrile
episode caused by laboratory-confirmed DENV infec-
tion. Seroconversion during the non-surveillance period
could not be classified as subclinical or symptomatic
infection since active surveillance was not performed
during that period. Symptomatic infection was further
categorized as non-hospitalized DF, hospitalized DF
(hDF) and hospitalized DHF. Clinical classification was
based on WHO 1997 guidelines [24]. Data from sub-
clinical and symptomatic DENV infections from 1998
to 2007 were used for the current analysis.
Laboratory dengue assays
Acute blood samples were tested by viral isolation [25]
and/or hemi-nested reverse transcriptase polymerase
chain reaction (RT-PCR) [26-29]. Acute and convalescent
blood samples were tested by DENV IgM/IgG enzyme-
linked immunosorbent assay (ELISA) [30]. If anti-dengue
IgM was ≥40 units and anti-dengue IgM:IgG ratio
was ≥1.8, the infection was considered as “primary”.
An infection was considered “secondary” if anti-dengue
IgM was ≥40 units and anti-dengue IgM:IgG ratio was
<1.8, or, if anti-dengue IgM was <40, there was ≥ two-fold
increase in anti-dengue IgG with an absolute value of
≥100 units for acute/convalescent sample pairs. In the
cohort studies, paired samples from periodic scheduled
blood collections were tested by dengue HAI and, if posi-
tive for seroconversion based on a ≥ four-fold rise in titer,
were confirmed by dengue PRNT.
Data management and terminology
Data managers independent of study investigators iden-
tified repeat DENV infections occurring in the same in-
dividual by name and birth dates from the relevant
datasets. The data was then anonymized and provided to
study investigators for further analysis.
“Primary” infection was presumed to be the first
DENV infection in an individual and was defined sero-
logically as described above. “Secondary” infection was
considered to be any subsequent infection after a pri-
mary infection and was defined serologically. “First,
second, third, and fourth” infections refer to the order of
sequential infections in an individual whether or not the
infection was actually detected. Second, third and fourth
infections were all considered to be “secondary” infec-
tions. “Infection one, two, and three” refer to the order
of sequential infections actually detected in an individual
during the study period (i.e., infection one was the first
detected infection, etc.).
Statistical methods and data analysis
Demographic characteristics were described and the
time between sequential infections was calculated by
subtracting dates of sample collection. For subclinical
infections (only available from the cohort studies), the
midpoint time between scheduled blood collections was
used as the time of infection. Chi-square test and odds
ratios (ORs) with 95% confidence intervals (CIs) were
used to compare proportions in clinical severity mea-
sures (e.g., hospitalization versus non-hospitalization,
DHF versus non-DHF). Fisher’s exact test was used to
compare DHF:DF ratios among different sequential sero-
type pairs. For continuous variables, one-way ANOVA
followed by Bonferroni multiple comparison correction
was used. Since the different datasets used for the
current evaluation came from studies and surveillance
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programs with different methodologies, quantitative ana-
lysis of risk factors for clinical severity was limited to DENV
infections in cohort subjects detected during active cohort
study surveillance and subsequent non-study hospital-
based passive surveillance (hereafter referred to as “cohort
extended dataset”). The duration of hospital-based passive
surveillance used in the cohort extended dataset was lim-
ited to five years after infection one to minimize unequal
chances of detecting sequential infections due to this
extended surveillance period. Multivariate binary logistic
regression was used to assess risk factors associated with
clinical severity. Data were analyzed using SPSS for
Windows (version 19) and Stata/MP 11.1 for Windows.
Results
Data from 38,740 laboratory-confirmed DENV infections
was available for evaluation. Among these infections, we
identified 502 individuals who had repeat infections
comprising 1,018 sequential DENV infections; 488 indi-
viduals had two detected infections and 14 had three
detected infections. Their demographic, serological, and
clinical characteristics are shown in Table 1. Details of
the 14 individuals with three documented DENV infec-
tions are given in Table 2. Because the number of such
individuals was small, infection three was excluded from
subsequent analyses.
Sixty-three percent (643/1,018) of repeat infections
were detected from public health samples or hospital-
based dengue studies through passive surveillance; 424
were from QSNICH and 219 were from KPPPH. The
remaining 375 infections were detected from prospective
cohort studies in KPP through active and passive sur-
veillance. Mean ages at infection one and infection two
captured during cohort studies versus hospital-based
passive surveillance are shown in Figure 1. As expected,
significant age differences were found among study/
surveillance types and locations. DENV infections were
clinically categorized into four groups: subclinical, non-
hospitalized DF (nhDF), hospitalized DF (hDF), and
DHF (all of which were hospitalized). The latter three
groups were considered to be symptomatic infections.
Among 29 hospitalized infections (16 infection one’s; 13
infection two’s), data was not available to determine
whether these were hDF or DHF. Ninety-eight infections
from cohort studies detected by dengue HAI serocon-
version outside the active study surveillance period had
indeterminate serotype and clinical severity. Infections
that could not be clinically categorized were removed
from analyses that required this information (e.g., DHF
versus DF, symptomatic versus subclinical).
Serologic response
Data on the acute serologic response (i.e., primary versus
secondary) at infection one was available for 347 individuals
Table 1 Demographic, serologic, and clinical characteristics
of individuals with repeat dengue virus infections
All data (n = 502
individuals)a
Cohort extended
dataset (n = 205)
Gender
Female 252 100
Male 237 95
Unknown 13 10
Age
At infection one (mean years ± SD) 7.6 ± 3.0 9.0 ± 1.7
At infection two (mean years ± SD) 11.2 ± 3.0 11.2 ± 2.0
Serologic response at
infection oneb
Primary 84 6
Secondary 263 59
Unknown (symptomatic) 15 -
Unknown (Subclinical/
nonhospitalized)
56 56
Unknown (Subclinical) 84 84
Clinical category at
infection onec
Symp. (DHF) 201 24
Symp. (DHF/hospitalized DF) 16 3
Symp. (hospitalized DF) 123 16
Symp. (non-hospitalized DF) 19 19
Symp. (hospitalized/non-
hospitalized DF)
3 3
Subclinical/non-hospitalized 56 56
Subclinical 84 84
Clinical category at
infection twoc
Symp. (DHF) 201 17
Symp. (DHF/hospitalized DF) 13 -
Symp. (hospitalized DF) 112 16
Symp. (non-hospitalized DF) 33 29
Symp. (hospitalized/
non-hospitalized DF)
1 1
Subclinical/non-hospitalized 42 42
Subclinical 100 100
a488 individuals had two detected infections; 14 had three detected infections.
bThe serologic response could not be categorized in 155 individuals; 140 could
not be categorized because they were either subclinical (n = 84) or had
seroconversion outside the active surveillance period in cohort studies (n = 56);
15 were symptomatic but had inadequate samples to determine serologic
response.
cSubclinical infections in cohort studies were identified by ≥ four-fold rise in
dengue hemagglutination inhibition (HAI) titers without detection of
symptomatic infection during the intervening surveillance period. Infections
captured outside the active study surveillance period by HAI without a
recognized hospitalization were marked as ‘subclinical/non-hospitalized’.
Hospitalized cases that did not have sufficient clinical information for clinical
categorization were marked ‘DHF/hospitalized DF.’ Four infections categorized
as DF but with uncertain hospitalization status were marked as ‘hospitalized/
non-hospitalized DF’.
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with symptomatic infections; 15 individuals with symp-
tomatic infection at infection one had insufficient
samples to determine serological response. Of these 347
individuals, 84 (24.2%) demonstrated a primary sero-
logic response and 263 (75.8%) a secondary response.
The mean age of individuals with a secondary response
at infection one was 7.5 ± 2.9 years, which was between
the mean age with a primary response at infection one
(5.7 ± 3.8 years; p < 0.001) and the corresponding infec-
tion two (9.9 ± 3.7 years; p < 0.001, Figure 2).
Sequential serotype pairs
All possible pairs of sequential infecting serotypes were
documented except for DENV-4 followed by DENV-3.
DHF in infection two was documented for all these
serotype pairs including DENV-4 followed by DENV-1
(Table 3). No sequential infections with the same serotype
were detected. Thirteen individuals for whom DHF/DF
classification in infection two was not available (marked as
DHF/hospitalized DF in Table 1) were not included in
Table 3. There was no significant difference in the ratio of
DHF to DF among the different sequential serotype pairs
regardless of the serologic responses. However, statistical
power was limited by the small numbers within each cell.
Time intervals between infections
The shortest time between any two sequential DENV in-
fections was 66 days (Table 4). The mean interval between
infection one and infection two was shorter when infec-
tion two was subclinical than when infection two was
symptomatic (1.9 vs. 4.1 years; p < 0.001). Every additional
year between sequential infections increased the risk of
hospitalization; the crude OR increased by 1.3 (95% CI
0.7-2.3), 1.9 (95% CI 1.5-2.4), and 3.2 (95% CI 2.0-4.9)
times each year when infection one had primary, secondary,
and unknown serologic response, respectively, but only
reached significance for the latter two (both p < 0.001). Sub-
clinical infections were only available from cohort studies,
whereas most of the symptomatic cases were captured from
hospital-based passive surveillance.
The number of individuals with each sequential sero-
type pair was relatively small, ranging from three with
DENV-4 followed by DENV-1, to 37 with DENV-1
followed by DENV-2. The intervals between infection
one and infection two were compared among the differ-
ent serotype pairs (Figure 3). DENV-3 followed by
DENV-4 had the longest interval (6.8 ± 1.8 years), which
was significantly longer than DENV-1 followed by DENV-
3 (2.8 ± 1.6 years, p = 0.001), DENV-1 followed by DENV-
2 (3.6 ± 1.8 years, p = 0.002), and DENV-3 followed by
DENV-2 (3.7 ± 2.2 years, p = 0.043). The other serotype
pairs with significant differences were DENV-3 followed
by DENV-1 (6.4 ± 2.7 years) compared to DENV-1
followed by DENV-3 (2.8 ± 1.6 years, p = 0.003) and
DENV-1 followed by DENV-2 (3.6 ± 1.8 years, p = 0.015).
These differences in time intervals may simply reflect the
Table 2 Data of individuals with three detected infections
Age at infection Serotypea Serologic responseb Clinical categoryc
Infection order 1 2 3 1 2 3 1 2 3 1 2 3
Indiv. Titers > 10d
1 0 8.7 12.8 14.9 ND NEG DEN4 ND S S SubC/nhDF DHF DHF
2 0 8.9 10.9 12.2 ND ND ND ND ND ND SubC SubC SubC
3 ND 10.5 10.8 10.9 NEG DEN1 NEG S S S nhDF/hDF hDF hDF
4 0 7.7 8.7 11.0 ND ND DEN2 ND ND S SubC/nhDF SubC/nhDF nhDF
5 4 7.5 8.5 10.5 ND ND ND ND ND ND SubC SubC SubC
6 0 7.9 9.2 12.2 ND ND ND ND ND ND SubC/nhDF SubC SubC
7 0 7.9 9.4 12.8 DEN1 NEG ND S S ND DHF nhDF SubC
8 4 9.0 12.3 12.9 ND ND DEN2 ND ND S SubC SubC DHF
9 ND 5.9 9.3 10.2 NEG ND ND S ND ND DHF SubC SubC
10 4 7.8 9.0 10.3 ND ND ND ND ND ND SubC/nhDF SubC SubC
11 ND 9.1 11.1 11.8 DEN1 DEN3 ND S S ND hDF nhDF SubC/nhDF
12 0 7.8 10.8 12.3 ND ND ND ND ND ND SubC/nhDF SubC/nhDF SubC
13 0 7.8 8.8 10.1 ND ND DEN2 ND ND S SubC/nhDF SubC/nhDF nhDF
14 ND 5.3 8.7 9.8 NEG DEN2 ND S S ND DHF nhDF SubC
aDengue virus (DENV) serotype detected by RT-PCR or viral culture. NEG = no virus detected. ND = RT-PCR not performed (no symptomatic infection occurred).
bS = secondary response. ND = not determined (no symptomatic infection occurred).
cSubC = subclinical DENV infection (captured by four-fold rise in dengue hemagglutination inhibition (HAI) titers without identified acute symptomatic DENV
infection); SubC/nhDF = subclinical/non-hospitalized dengue fever (DF) (infections captured by four-fold rise in HAI titers outside the active study surveillance
period; see Methods for detailed explanation); nhDF = non-hospitalized DF; hDF = hospitalized DF.
dNumber of DENV serotypes with HAI titer >10 prior to infection one.
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serotype circulation patterns in the general population.
The mean time between infection one and infection two
was not significantly different based on whether infec-
tion one was associated with a primary serologic re-
sponse (4.2 ± 2.5 years) or a secondary response (3.9 ±
2.4 years); p = 0.392.
Analysis of cohort extended dataset
To determine relationships between characteristics of
the sequential DENV infections and clinical severity at
infection two, we limited analysis to infections in cohort
subjects only, from both active study surveillance and
subsequent non-study hospital-based passive surveil-
lance. Of the 502 individuals with repeat detected DENV
infections, 158 had their infections captured solely from
cohort study surveillance. When subsequent non-study
hospital-based passive surveillance was included an
additional 37 cohort subjects with repeat infections were
identified. Gender, mean age at each infection and
clinical categorization are shown in Table 1. A compari-
son of characteristics of these 158 and 37 individuals are
presented in the Additional file 1.
Univariate analysis of association with clinical category
Comparisons were done for hospitalized versus non-
hospitalized dengue and DHF versus non-DHF. The risk
of hospitalization at infection two was increased by 1.8
(95% CI 1.21-2.67) for each additional year between
sequential infections. Hospitalization at infection one
also increased the risk of hospitalization at infection two
(OR 4.58, 95% CI 1.37-15.24) while having DHF at infec-
tion one did not. Age at infection one was not associated
with hospitalization at infection two. Similar relation-
ships were found when examining risk for DHF versus
non-DHF; odds ratios are provided in Table 5.
Multivariate analysis of association with clinical category
Using a binary logistic regression model, hospitalization
at infection two was more strongly associated with time
between sequential infections (OR 2.35, 95% CI 1.39-
3.99). Hospitalization at infection one continued to pose
an increased risk for hospitalization at infection two;
DHF and increasing age at infection one did not. Asses-
sing risk factors associated with DHF at infection two,
results were consistent with the crude analysis: increasing
time between sequential infections and hospitalization at
infection one heightened the risk for DHF at infection
Non-hospitalized DF
/Subclinical
Non-hospitalized DF
Hospitalized DF
Hospitalized DF
/DHF
DHF
Subclinical
 mean age=10.1
(n=375)
 mean age=10.0
(n=219)
 mean age
=indeterminate
(n=0)
 mean age=8.6
(n=424)
Figure 1 Age at time of infection by location. Data used in this study were collected from two locations: Kamphaeng Phet and Bangkok,
Thailand. Age distributions of infections detected in each dataset for each location are shown.
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Figure 2 Mean age at infection one and infection two (with
95% CIs) along with the mean time interval between infections
grouped by serologic response at infection one.
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two, whereas DHF at infection one did not. Variables that
were included in the analysis are listed in Table 5.
Discussion
Using data from over 17 years of hospital-based passive
surveillance and nine years of cohort studies, we found
502 individuals with repeat DENV infections among
38,740 DENV infections in our database. In the two
cohort studies, a total of 1806 individuals experienced at
least one DENV infection; 205 (15.8%) of these individuals
were observed to have experienced repeat infections of
which 72% of second detected infections were subclinical.
This represents one of the largest samples of repeat DENV
infections reported to date.
The mean time interval between sequential infections
was 3.5 ± 2.4 years. Considering only symptomatic repeat
infections, the mean time interval between the first and
second detected infections was 4.3 ± 2.4 years, higher
than what we reported in 2007 from an analysis of a
smaller dataset from QSNICH collected from January
Table 3 Ratio of dengue hemorrhagic fever to dengue fever (DHF:DF) at infection two in individuals with two
symptomatic infections according to sequential serotype pair and serologic response at infection one
Serotype
at
infection
one
Serological
response at
infection
one
DHF:DF ratio
Serotype at infection two
DENV-1 DENV-2 DENV-3 DENV-4 Anya
DENV-1 Primary - 9.0 (9:1) Ind. (4:0) 2.0 (8:4) 3.3 (23:7)
Secondary - 1.2 (13:11) 1.3 (5:4) 0.6 (3:5) 1.3 (31:23)
Allb - 1.8 (24:13) 2.3 (9:4) 1.1 (11:10) 1.7 (58:34)
DENV-2 Primary 2.0 (2:1) - Ind. (1:0) 1.0 (1:1) 2 (6:3)
Secondary 5.0 (5:1) - 4.0 (4:1) 5.0 (5:1) 2.6 (21:8)
Allb 3.5 (7:2) - 5.0 (5:1) 3.0 (6:2) 2.3 (27:12)
DENV-3 Primary 3.0 (3:1) 1.0 (2:2) - 1.0 (1:1) 1.1 (9:8)
Secondary 2.0 (4:2) 3.5 (7:2) - 0.6 (3:5) 1.6 (19:12)
Allb 2.3 (7:3) 2.3 (9:4) - 0.7 (4:6) 1.4 (28:20)
DENV-4 Primary - - - - -
Secondary 0.5 (1:2) 0.5 (1:2) - - 0.7 (4:6)
Allb 0.5 (1:2) 1.0 (2:2) - - 0.8 (5:6)
Anya Primary 2.7 (8:3) 3.6 (18:5) Ind. (6:0) 1.6 (11:7) 2.2 (55:25)
Secondary 1.2 (16:13) 1.7 (38:22) 1.1 (10:9) 1.2 (20:17) 1.4 (127:88)
Allb 1.5 (24:16) 2.3 (63:28) 1.8 (16:9) 1.3 (32:25) 1.6 (192:118)
A total of 323 of 502 sequential dengue virus (DENV) infections were symptomatic at both infection one and two. Of these 323, 13 without DHF/DF classification
at infection two (marked as DHF/hospitalized DF in Table 1) were not included in this table. Statistical power was limited by the small numbers within each cell.
aIncludes any case captured regardless of knowing or not knowing the infecting serotype.
bIncludes all cases captured regardless of serologic response at infection one. Therefore, ones with unknown response are also included.
Ind = indeterminate.
Table 4 Time interval between sequential dengue virus infections by clinical category at infection one and two
Interval between infections (yrs)
Clinical categorya All data (n = 502) Cohort extended datasetc (n = 195)
Infection one Infection two N Mean Min Max N Mean Min Max
Any Any 502 3.45 0.18 12.57 195 1.85 .27 4.96
Subclinicalb Subclinicalb 45 1.74 0.78 3.25 45 1.74 0.78 3.25
Subclinicalb Symptomatic 26 3.03 0.65 12.26 21 1.84 0.65 4.22
Symptomatic Subclinicalb 23 2.15 0.77 4.96 23 2.15 0.77 4.96
Symptomatic Symptomatic 323 4.27 0.18 12.57 21 2.35 0.27 4.28
aClinical category at infection one and two.
bSubclinical infections were only captured from cohort studies. Symptomatic infections include all symptomatic infections from Bangkok and Kamphaeng Phet. 56
infection one’s and 42 infection two’s were unable to be clinically categorized as symptomatic or subclinical due to occurrence out of the active study surveillance
period and not seeking hospital care (listed as ‘Any’ in the table).
cOnly infections in cohort subjects were included in this subgroup; includes infections detected from non-study hospital-basedpassive surveillance within five
years after infection one.
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1994 to February 2005 [8]. Similar to Montoya et al.
[31], we found that the time from a subclinical infection
to a subsequent subclinical infection (1.7 ± 0.8 years)
was shorter than to a subsequent symptomatic infection
(3.0 ± 2.9 years); p = 0.006.
The shortest duration between sequential symptomatic
DENV infections in our study was approximately two
months suggesting that heterologous cross-protection
lasts for a minimum of two months (although the typical
duration may have been longer). This finding is consist-
ent with the serial experimental inoculations of DENV
into human volunteers in the 1940s by Sabin [11]. It is
possible that the period of complete cross-protection
varies according to each particular sequential serotype
pair. Despite our relatively large dataset, the number of
symptomatic infections with knownserotype was not
large enough to demonstrate significant differences
among different serotype pairs. Time intervals between
serotype pairs would also be affected by the timing of
particular serotype predominance in these communities
during the 17-year study period, which would represent
a confounding factor in this analysis.
Analysis of serologic responses in symptomatic infec-
tions revealed that, for 84 individuals, infection one was in
fact their first DENV infection, indicating that infection
two was their second DENV infection. In contrast, a sec-
ondary response in infection one may have represented a
first, second, or third DENV infection since a secondary
serologic response at the first infection could theoretically
have been due to prior Japanese encephalitis virus (JEV)
Figure 3 Time between sequential infections versus each sequential serotype pair (only individuals with known serotypes for both
sequential infections are included). Time between sequential infections (N = 187) were plotted in ordinal. Numbers with known serologic
response at infection one are shown.
Table 5 Univariate (crude) and multivariate (adjusted) analysis of factors predicting hospitalization and DHF at
infection two
Odds ratio (95% CI) of hospitalization over
non-hospitalization at infection two
Odds ratio (95% CI) of DHF over non-DHF
at infection two
Crude Adjusted Crude Adjusted
Time between infections 1.80* 2.35* 1.62* 3.83*
(1.21-2.67) (1.39-3.99) (1.27-2.06) (1.71-8.59)
Age at infection one 1.06 1.45 0.97 2.11*
(0.79-1.40) (0.97-2.16) (0.72-1.29) (1.13-3.93)
Severity at infection one (non-hospitalized as reference)
DHF 0.87 0.76 2.26 2.70
(0.19-4.05) (0.14-4.17) (0.44-11.66) (0.39-18.86)
Hospitalized dengue 4.58* 4.22* 5.84* 6.23*
(1.37-15.24) (1.18-15.07) (1.32-25.79) (1.20-32.40)
*Significant at p < 0.05.
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vaccination or natural JEV exposure. Serologic response
was not included in our quantitative analysis, however,
because a large portion of the cohort extended dataset
consisted of subclinical infections for which this infor-
mation was not available. Instead, we included age at in-
fection one to adjust for the outcome’s association with
serologic response, presuming that older individuals
were more likely to have had prior DENV infections.
Similar to our previous report in which we found a
longer interval between sequential infections to be asso-
ciated with symptomatic rather than subclinical infection
at infection two, both crude and adjusted odds ratios of
the cohort extended dataset demonstrated that a longer
interval between sequential infections increased the risk
of hospitalization and DHF at infection two. Other stud-
ies have similarly found that the time between sequential
infections is important in determining the severity of the
later infection [6,8,30].
We found that hospitalization at the first detected
DENV infection was associated with an increased risk
for hospitalization and DHF at the second detected in-
fection. Although DHF at infection one did not similarly
show a significant association, this may have been due to
the limited number of DHF cases. These findings sup-
port the notion of individual genetic predisposition for
more severe dengue disease. Other studies have found
associations between specific HLA classes and disease
severity [32-34]; a summary of such associations has
been published by Stephens et al. [32]. Other genetic
associations have been reported between DF and DHF
such as those relevant to TNF-α, iNOS or p47phox [35-37].
Interestingly, among those individuals who had three
sequential infections detected in our study (Table 2),
two (patients 2 and 5) had subclinical infection with all
three infections and two (patients 1 and 8) had DHF
with the third infection, suggesting some degree of
consistency in severity among some individuals across
their infections. Nevertheless, it is also possible that
parents of children with previous dengue admissions or
DHF may have been more likely to bring their child to
medical attention during subsequent episodes.
Our study has several limitations. First, hospital-based
passive surveillance would not have identified subclinical
and non-hospitalized symptomatic infections. The ability
to detect subclinical and mild infections was constrained
to relatively short time periods and small groups of indi-
viduals in cohort studies. Therefore, analyses of the full
dataset may have been confounded when evaluating, for
example, the time between sequential infections which
may have been underestimated for mild infections. Fur-
thermore, confounders in the analysis of the cohort
extended dataset may not have been equally distributed
over the whole analysis period due to the inclusion of
non-study hospital-based passive surveillance data.
Second, the timing of subclinical infection could not be
determined definitively and was instead estimated at the
midpoint between serial scheduled blood collections. This
approximation may have affected our analyses of time
between sequential infections in an unpredictable manner.
Third, in the hospital-based passive surveillance, the
chance of a patient revisiting the same hospital was less
likely in Bangkok than KPP given the greater abundance
of healthcare facilities in Bangkok. So patients admitted
twice to QSNICH may have been more likely to have
severe disease with both sequential infections.
Conclusions
Our study provides a unique opportunity to evaluate a
large number of repeat DENV infections over an ex-
tended period of time. This was made possible by the
long-standing dengue testing that has been performed at
the same locations in Thailand over many years. Our
findings provide further evidence of the importance of
heterologous cross-protection and the possibility of gen-
etic predisposition in determining the clinical presenta-
tion of DENV infection. These findings should inform
ongoing investigations of DENV transmission dynamics,
development of vaccines and dengue biomarkers.
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